A phase I study of the safety and tolerability of intravesical administration of SCH 721015 [interferon alpha-2b] in patients with transitional cell carcinoma of the bladder

Trial Profile

A phase I study of the safety and tolerability of intravesical administration of SCH 721015 [interferon alpha-2b] in patients with transitional cell carcinoma of the bladder

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2009

At a glance

  • Drugs Interferon alpha-2b (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 06 May 2009 Actual initiation date (6 Oct 2006) added as reported by M.D. Anderson Cancer Center record.
    • 03 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top